

Yallappa, S., Amer, T., Jones, P., Greco, F., Tailly, T., Somani, B., Eronini, N. U. and Aboumarzouk, O. M. (2018) Natural history of conservatively managed ureteral stones: analysis of 6600 patients. *Journal of Endourology*, 32(5), pp. 371-379. (doi:10.1089/end.2017.0848)

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

http://eprints.gla.ac.uk/158261/

Deposited on: 02 March 2018

Enlighten – Research publications by members of the University of Glasgow <a href="http://eprints.gla.ac.uk">http://eprints.gla.ac.uk</a>

Natural History of Conservatively Managed Ureteric Stones from a cumulative analysis of 6600 patients (DOI: 10.1089/end.2017.0848)

© Mary Ann Liebert, Inc. DOI: 10.1089/end.2017.0848

# **Natural History of Conservatively Managed Ureteric Stones:** analysis of 6600 patients

Sachin Yallappa<sup>1, 2</sup>, Tarik Amer<sup>1, 2</sup>, Patrick Jones<sup>3</sup>, Francesco Greco<sup>4</sup>, Thomas Tailly<sup>4</sup>, Bhaskar K Somani<sup>3,4</sup>, Nkem Umez-Eronini<sup>1</sup>, Omar M Aboumarzouk<sup>1, 2, 4, 5</sup>

- 1 Glasgow Urological Research Unit, Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK
- 2 University of Glasgow, School of Medicine, Dentistry & Nursing, Glasgow, UK
- 3 University Hospitals Southampton NHS Trust, Southampton, UK
- 4 EAU Young Academic Urologists Group, Arnhem, The Netherlands.
- 5 Islamic Universities of Gaza, College of Medicine, Gaza, Palestine

Urolithiasis and its management has become a global growing concern posing both clinical and economic burden for healthcare systems (1). With the steady rise of populations, the annual prevalence of urinary tract stones is increasing and as well as the requirement for hospital visits (2).

Ureter stone has a lifetime prevalence of 10% to 15% and is one of the most common urological presentations in the emergency department (3, 4). Patients experience severe flank pain radiating to groin because of sudden obstruction of the ureter, with associated risks of hydronephrosis, renal damage, infection of the urinary tract and severe sepsis (5).

Ureteric stones can be managed by different modalities; expectant management with spontaneous passage of the stone, with or without medical expulsive therapy as an adjuvant (6). Those that fail to pass stones spontaneously will require more invasive options.

In the absence of infection, severe obstruction, renal impairment and uncontrollable pain expectant management of spontaneous stone passage is preferred, as long as the passage is likely in a reasonable time frame (7, 8). There is no clear consensus of recommendations for expectant management of ureteric stones either by the American urological association (AUA) or by the European association of urology (EAU), mainly due to studies with insufficient supporting data. However, current AUA guideline recommends trial of spontaneous passage for  $\leq 10$  mm stone (9) and EAU recommends the same management for 'small' ureteral stones referring to  $\leq 6$ mm stones, if active removal is not indicated (10).

It is very important to understand the natural history of ureter stone disease especially to recognize the cohort of patients and their stone characteristics, who would expel the stone spontaneously and also to understand the time frame they can be safely observed with least undesirable complications.

However, current literature lacks high-level evidence on spontaneous passage rates.

Therefore, we aimed to conduct a systematic review of all randomised trials to better establish an evidence based natural history of stone expulsion, which can aid management

Downloaded by GLASGOW UNIVERSITY LIBRARY/Swets / 88135888 from online.liebertpub.com at 03/02/18. For personal use only.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof Natural History of Conservatively Managed Ureteric Stones from a cumulative analysis of 6600 patients (DOI: 10.1089/end.2017.0848)

of ureteral stones. In addition, we will look at all studies that specifically researched the natural history of stone expulsion.

# Methodology

#### Search strategy

The systematic review of the literature was performed using Cochrane and PRISMA guidelines (11, 12). The search strategy included the following databases: The US National Library of Medicine's life science database (MEDLINE) (1980- August 2017), EMBASE (1980-August 2017), Cochrane Central Register of Controlled Trials - CENTRAL (in The Cochrane Library - 2017), CINAHL (1980- August 2017), Clinicaltrials.gov, Google Scholar and Individual urological journals.

Search terms used in conjunction with each other included: 'urolithiasis', 'urinary calculi', 'renal calculi', 'ureteric calculi', 'urinary stones', and 'Randomized controlled trial'.

Medical Subject Headings (MeSH) phrases included:

- (("Calculi"[Mesh] OR "Urinary Calculi"[Mesh] OR "Kidney Calculi"[Mesh]) AND
   "Randomized Controlled Trial" [Publication Type])
- (("Adrenergic Alpha-Antagonists"[Mesh]) AND "Urinary Calculi"[Mesh]) AND
   "Randomized Controlled Trial" [Publication Type]))
- (("Calcium Channel Blockers"[Mesh]) AND "Urinary Calculi"[Mesh]) AND
   "Randomized Controlled Trial" [Publication Type]))

#### **Study Selection**

All languages were included if data was extractable, also references of searched papers were evaluated for further studies for potential inclusion. Authors were contacted wherever the data was not available or not clear, to be able to adequately assess inclusion of their study. If data was not extractable, provided or clarified, the study was excluded.

Four reviewers (SY, TA, and OA) identified studies that appeared to fit the inclusion criteria for full review. Four reviewers (SY, TA, BS, and OA) independently selected studies for inclusion. Disagreement between the authors in study inclusion was resolved by consensus.

Data of each included study was independently extracted initially by 3 authors (SY, TA, and PJ) after which a senior author (OA) extracted the data independently and cross checked each data extraction to ensure quality assurance of data across the board.

All studies comparing a treatment modality to a placebo were included. Published trials on adult patients of placebo arms of stone expulsions and all studies looking at the natural history of stone expulsions were included. We excluded studies on children or stone management studies that did not include a non-treatment arm, ie trials of ESWL, URs, or PCNLs in isolation, with no placebo non-treatment group. We extracted data of the placebo arms of trials, where no medical expulsive therapy or surgical treatment has been carried out, to be able to determine the natural course of stone expulsion and cumulatively analysed these with that of studies reporting the natural history.

The following variables were extracted from each study: patient and stone demographics, expulsion rates, expulsion times, and side effect of the medication. The data of each study was grouped into a meta-analysis, in an intention to treat basis.

## **Statistical Analysis and Quality Assessment**

The data of the placebo arms of each trial was extracted to represent the natural history of stones. We divided each subcategory into overall expulsion rate, stones in the upper, mid, or lower ureter, and stones <5mm and >5mm in size. The results were depicted as percentages and an intention to treat basis was used.

We included all studies looking at the natural history of stone expulsion rates as well as RCTs as these studies are more controlled and more reliable that no intervention was done for the placebo arm and the results are more likely to represent the true natural history of stone expulsion. An assessment of the methodological quality of the RCT was conducted in line with the Cochrane handbook (12).

#### Results

#### Literature search

The literature search identified 876 studies, of which 697 were excluded due to non-relevance based on titles and 179 excluded due to non-relevance based on the abstracts (Figure 1). Full manuscripts were evaluated in 91 studies, of which 22 studies were excluded due to not meeting inclusion criteria. The remaining 70 studies were included that reported on the spontaneous passage of ureteral stones without any medical or surgical intervention (Figure 1) (8,13-81).

Characteristics of the included studies:

The trials span over 3 decades from 1994 with the latest in 2017. While the natural history papers spanned from 1977-2017. We were unable to obtain full manuscripts prior to this date to analyse, therefore excluded. There was a total of 6642 patients conservatively treated. The age range was between 17 and 74 years of age. All the natural history studies looked at stone expulsion with no intervention. Table 1 depicts the patient and stone demographics.

All the RCTs reported on the spontaneous stone passage rates with no intervention. Regarding stone location within the ureter, 15 studies reported on upper tract stones, 10 on mid ureteric stones, and 65 on distal ureter stones. Nine studies reporting on more than one location (24, 38, 40, 42, 44, 47, 55, 65, 69). Sixteen studies reported on stones <5mm (29, 33, 34, 39, 40, 44, 46, 48, 55, 69, 75, 76, 77, 79, 80, 81), while 19 reported on stones >5mm.(22, 24, 29, 30,33, 35, 39, 40, 44, 48, 55, 57, 60, 69, 75, 76, 77, 79, 81). Twelve of the studies reported on stones in the distal ureter and >5mm in size (22, 24, 29, 30, 35, 48, 57, 60, 75, 76, 77, 81), while other no studies were found that data can be extracted for stones combining locality and stone size.

Downloaded by GLASGOW UNIVERSITY LIBRARY/Swets / 88135888 from online.liebertpub.com at 03/02/18. For personal use only.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

### **Cumulative analysis results**

Stone Passage:

Overall 64.4% patients successfully passed their stones without any medical or surgical interventions (table 2).

Dividing the stones in locality: 49.1% of upper ureteric stones, 58.1% of mid ureteric stones, and 68.1% of distal ureteric stones passed spontaneously (table 2).

Groups based on size: 75.3% of stones <5mm passed spontaneously irrespective of location as opposed to 61.6% of stones >5mm that passed spontaneously (table 2).

Requiring Rehospitalisation:

Nearly 5% required rehospitalisation due to worsening of their condition, ie pain not controlled by analgesics or developed a sepsis (162/3035).

Side Effects:

Only 1% of patients experienced side effects from analgesia provided (31/2745). These included nausea and vomiting being the most common, other side effects included: headaches, dizziness, rhinitis, fatigue, hypotension, diarrhoea, and heartburn.

#### Methodological quality assessment

All the studies were reported as Randomised controlled studies, ergo considered high quality studies. Figure 2 depicts the summary of the quality assessment based on the reviewing author's judgement of risks of bias for each included study. Of the 63 trials only 12 had no risk of bias to note (17, 30, 32, 33, 37, 54, 55, 62, 65, 66, 67, 81).

One trial did not have appropriate randomisation (50). We found that the blinding was the main differential aspect of the quality assessment between the studies. Only 14 had adequate blinding (13, 17, 22, 23, 30, 33, 37, 53, 55, 62, 65, 66, 67, 81). Furthermore, concealment was not mentioned in many of the trials with 50 not mentioning how they concealed their study giving leaving an unclear decision on concealment, 2 trials made no attempts at concealment (49, 71), while 11 trials had adequate concealment (17, 30, 32,

33, 37, 54, 45, 62, 65, 66, 81). Three studies had incomplete outcomes reporting bias (47, 49, 50). Two other studies had other risk of bias (19, 60).

Regarding the natural history studies, these were of low evidence as they were all cohort retrospective or prospective studies, however each study meticulously delineated their methodology protocol and did not have any evidence of selection or reporting bias, and no missing data.

#### Discussion

Although it is demonstrated in various studies that small ureteric stones pass spontaneously (8), the urologist are frequently challenged with the decision of whether to observe a stone in expectation of spontaneous passage, or to intervene surgically (82). Studies have also demonstrated that spontaneous passage of ureteric stone is size and location dependent (66, 71). The more the distal the stone is in the ureter, the greater is the probability of spontaneous passage. Additionally, smaller stones are prone to pass quickly when compared to larger stones (8).

We investigated the outcome of ureter stones in 6642 patients treated by expectant management. The incidence of spontaneous passage relating both stone size and location was determined from these collated studies. The rate of spontaneous passage for stones smaller than 5 mm was 75% compared to 62% for those larger than 5 mm, irrespective of their position in the ureter at the time of presentation. While stones discovered in the distal third of the ureter had a spontaneous passage rate of 68%, compared with the mid third of 58%, and the proximal third of 49%. With a low complication rate.

#### **Stones Expulsion Rates**

Consideration of various factors is essential to determine the optimal treatment for patients with ureteric stone. Canadian urological association guidelines divides these factors broadly into four categories namely; (i) stone factors consisting of location, size, composition, presence and duration of obstruction, (ii) clinical factors consisting of symptom severity, patient's expectations, associated infection, obesity, coagulopathy, hypertension and solitary kidney, (iii) anatomic factors like horseshoe kidney,

ureteropelvic junction obstruction and renal ectopia and (iv) technical factors of availability of equipment, expertise and cost. The guideline also emphasizes the selection of any modality of treatment to be based on 'achieving maximal stone clearance with minimal morbidity to the patient (7).

Various studies have demonstrated spontaneous stone passage rate in relation to the stone size; Ueno et al in 1977 showed spontaneous passage rates of 38% and 1.2% in stones of <4 mm and >6 mm (71), Hubner et al in 1993 reported a communitive analysis of the literature, which showed 57% spontaneous passage of stones <4mm, 4 to 6 mm stones passed in 35%, and only 8% in those with stones larger than 6mm (66). Coll et al demonstrated close relationship of stone size and spontaneous passage. They reported stone size of 1, 4, 7 and 10 mm had spontaneous passage rate of 87%, 72%, 47%, and 27%, respectively (65).

The locations of stones also have been well recognized as an important factor in the spontaneous expulsion rate. In 1991, Morse et al demonstrated spontaneous stone passage rate of 71% from the distal 46% from the mid and 22% from the proximal ureter (68). Hubner et al showed spontaneous passage in 38% of stones located in the distal third of the ureter, compared with 15% in the mid third and 18% of stones in the proximal third (66). In a retrospective radiologically followed study using unenhanced CT scan, Coll et al, 2002, reported spontaneous stone passage rate of 75% in distal ureter, 60% for mid ureteral stones and 48% for stones in the proximal ureter (65). Sfoungaristos et al, 2012, noted spontaneous passage of 50% distal ureter stones, including stones in VUJ and 90% passage rate for mid ureter stones (69).

All these studies highlighted how there are discrepancies in the percentages of stone expulsion across the board.

#### Timing of stone passage

Though these natural history of stone studies, gave a rough idea of the rates of spontaneous stone passage, evidence from RCTs, has shown heterogenic results. The cumulative analysis in this review has yielded a more precise account spontaneous stone passages. However, there remains a great disparity in the time to stone passage between

all studies, with a wide range from 1 to 4 weeks. Canadian urology guidelines (CUA) and European association of urology recommend 90% of chance of spontaneous passage of stones less than 5 within 40 days (7,10). This review has found that the majority of stone expulsions were within 4 weeks, with an average of about 17 days.

Nonetheless, this was limited by the fact that all the studies included had limited their follow up period to this range, with no longer follow up periods. This was largely based on patient safety. Ergo it can be deemed safe practice to consider treatment after of a stone if it has not passed after 4 weeks.

#### Safety

The rate of complications has been shown have a direct relation to the duration of symptoms. Twenty percent of patients have complications if symptoms are more than 4 weeks when compared to 7% if symptoms are less than 4 weeks in duration (66). The current study revealed that only 5% required readmission and out of which only 1.1% had minor side effects in relation to the analgesia used.

#### Implications for practice

Reasonably easy accessibility of equipment (shock wave lithotripsy, semirigid and flexible ureteroscopes) increase in number of trained endourologist and patient expectations has not only expanded the indications for intervention for ureteric stone but also has spawned significant increase in ureteroscopic procedure in last 10years (1, 8). Unfortunately, all form of procedures does come with certain risks.

Observation or expectant management of stone, until stone expels, is one of commonest management option for ureteric stone and appears attractive as it avoids invasive procedure however is associated with ambiguity and uncertainty, pain, potential loss of renal function and most importantly for many, loss of work and family commitments (70).

The continuously debated topic of assisting stone expulsion with medical therapy adds an added question. As shown,  $\alpha$ -blockers, specifically tamsulosin, can increase stone expulsion rates of stones in the distal ureter and of those of >5mm. Overall can increase stone expulsion rates by at least 14% (6, 83, 84, 85).

Furthermore, the cost benefit of conservatory managed stones can also sway decision to avoid treatment. In the United States, it's reported that expectant (observation) management of ureteric stones has a \$1200 cost advantage for distal ureteral stones and a \$400 for proximal ureteral stones (86).

We believe that current study is the largest cohort evaluation of natural history of ureteric stones and redefines the rate of passage of stones in relation to the size and location compared to previous published literature and current international urolithiasis guidelines. This also briefly gives an idea on the complication rate involved during the observation for the ureteric stones.

#### Conclusion

Expectant management has undeniable role in the treatment of ureteric stone patients. The outcome is largely determined on the stone size and location of the stone. Most ureteral stones <5mm, especially those located in the mid and distal ureter, will pass spontaneously. Hence it is acceptable for the urologist to observe for spontaneous stone passage for a period of time. Appropriate follow up of these patients is obligatory to avoid complications. If spontaneous passage does not occur within 4 weeks period, intervention is recommended. More importantly, this information helps to reduce patients' anxiety and supports them to make an evidence based informed decision about conservative management as opposed to invasive treatment.

# References

- Turney, Benjamin W., John M. Reynard, Jeremy G. Noble, and Stephen R. Keoghane. "Trends in Urological Stone Disease." *BJU International* 109, no. 7 (2012): 1082-087
- http://www.ons.gov.uk/peoplepopulationandcommunity/populationand migration/populationestimates/ (accessed Aug 2017)
- Rukin, Nicholas J, Zain A Siddiqui, Edmund C P Chedgy, and Bhaskar K Somani.
   "Trends in Upper Tract Stone Disease in England: Evidence from the Hospital Episodes Statistics Database." *Urologia Internationalis* 98, no. 4 (2017): 391-396
- Elton TJ, Roth CS, Berquist TH, Silverstein MD. A clinical prediction rule for the diagnosis of ureteral stone in emergency departments. J Gen Intern Med. 1993;8:57–62
- Iravani, Omid, Ern-Wei Tay, Boon-Huat Bay, and Yee-Kong Ng. "Unilateral Ureteric Stone Associated with Gross Hydronephrosis and Kidney Shrinkage: A Cadaveric Report." *Anatomy & Cell Biology* 47, no. 4 (2014): 267-70
- 6. Amer, Osman, Johnstone, Mariappan, Gupta, Brattis, Jones, Somani, Keeley, and Aboumarzouk. "Medical Expulsive Therapy for Ureteric Stones: Analysing the Evidence from Systematic Reviews and Meta-analysis of Powered Double-blinded Randomised Controlled Trials." *Arab Journal of Urology* 15, no. 2 (2017): 83-93
- 7. Ordon, Michael, Andonian, Sero, Blew, Brian, Schuler, Trevor, Chew, Ben, and Pace, Kenneth T. "CUA Guideline: Management of Ureteral Calculi." *Canadian Urological Association Journal (CUAJ)* 9, no. 11 12 (2015): E837-E851
- 8. Miller, and Kane. "TIME TO STONE PASSAGE FOR OBSERVED URETERAL CALCULI: A GUIDE FOR PATIENT EDUCATION." *The Journal of Urology* 162, no. 3 (1999): 688-91
- Assimos, Dean, Amy Krambeck, Nicole L Miller, Manoj Monga, M Hassan Murad, Caleb P Nelson, Kenneth T Pace, Vernon M Pais, Margaret S Pearle, Glenn M Preminger, Hassan Razvi, Ojas Shah, and Brian R Matlaga. "Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART I." *The Journal of Urology* 196, no. 4 (2016): 1153-60

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof Natural History of Conservatively Managed Ureteric Stones from a cumulative analysis of 6600 patients (DOI: 10.1089/end.2017.0848)

- Turk, Petaik, Sarica, Seitz, Skolarikos, Straub, and Knoll. "EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis." *European Urology* 69, no. 3 (2016): 468
- Higgins, Julian PT, Thompson, Simon G, Deeks, Jonathan J, and Altman, Douglas G.
   "Measuring Inconsistency in Meta-analyses." *British Medical Journal* 327, no. 7414 (2003): 557-60
- 12. Higgins JP GS. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration; 2011. Available from: <a href="https://www.cochrane-handbook.org">www.cochrane-handbook.org</a>.
- 13. Abdel-Meguid TA, Tayib A, Al-Sayyad A. Tamsulosin to treat uncomplicated distal ureteral calculi: a double blind randomized placebo-controlled trial. *Canadian Urological Association Journal (CUAJ)*. 2010;17(3):5178-83
- 14. Agrawal, Madhusudan, Gupta, Manoj, Gupta, Apurva, Agrawal, Akash, Sarkari, Avijit, and Lavania, Prashant. "Prospective Randomized Trial Comparing Efficacy of Alfuzosin and Tamsulosin in Management of Lower Ureteral Stones." *Urology* 73, no. 4 (2009): 706-09
- 15. Ahmad, Hussain, Waqar Azim, Muhammad Akmal, Badar Murtaza, Arshad Mahmood, Amir Nadim, and Khubaib Shahzad. "MEDICAL EXPULSIVE TREATMENT OF DISTAL URETERAL STONE USING TAMSULOSIN." *Journal of Ayub Medical College, Abbottabad : JAMC* 27, no. 1 (2015): 48-50
- 16. Ahmed, Abul-fotouh Abdel-maguid, and Abul-yazid Saad Al-sayed. "Tamsulosin versus Alfuzosin in the Treatment of Patients with Distal Ureteral Stones: Prospective, Randomized, Comparative Study." *Korean Journal of Urology* 51, no. 3 (2010): 193-97
- 17. Al-Ansari, Al-Naimi, Alobaidy, Assadiq, Azmi, and Shokeir. "Efficacy of Tamsulosin in the Management of Lower Ureteral Stones: A Randomized Double-blind Placebo-controlled Study of 100 Patients." *Urology* 75, no. 1 (2010): 4-7
- 18. Aldemir, Mustafa, Yusuf Üçgül, and Emre Kayıgil. "Evaluation of the Efficiency of Tamsulosin and Rowatinex in Patients with Distal Ureteral Stones: A Prospective, Randomized, Controlled Study." *International Urology and Nephrology* 43, no. 1 (2011): 79-83

- 20. Bajwa M RJ, Rahim J, et al. Efficacy of Tamsulosin for clearance of lower ureteric stones. Pakistan Journal of Medical and Health Sciences. 2013;7(3):Jul-Sept 769-72
- 21. Balci, Melih, Altug Tuncel, Omur Aydin, Yilmaz Aslan, Ozer Guzel, Ugur Toprak, Fazli Polat, and Ali Atan. "Tamsulosin versus Nifedipin in Medical Expulsive Therapy for Distal Ureteral Stones and the Predictive Value of Hounsfield Unit in Stone Expulsion." *Renal Failure, 2014, Vol.36(10), P.1541-1544* 36, no. 10 (2014): 1541-544
- 22. Borghi, Loris. "Nifedipine and Methylprednisolone in Facilitating Ureteral Stone Passage: A Randomized, Double-blind, Placebo-controlled Study. (J Urol 1994;152:1095-1098) (Abstract)." *JAMA, The Journal of the American Medical Association* 272, no. 24 (1994): 1884C
- 23. Çervenàkov, Fillo, Mardiak, Kopečnú, Šmirala, and Labaš. "Speedy Elimination of Ureterolithiasis in Lower Part of Ureters with the Alpha 1-blocker Tamsulosin."

  International Urology and Nephrology 34, no. 1 (2002): 25-29
- 24. Chau, Lysander Hin, Tai, Dominic Chi Kin, Fung, Berry Tat Chow, Li, James Cheuk Man, Fan, Chi Wai, and Li, Michael Ka Wah. "Medical Expulsive Therapy Using Alfuzosin for Patient Presenting with Ureteral Stone Less than 10 Mm: A Prospective Randomized Controlled Trial." *International Journal of Urology* 18, no. 7 (2011): 510-4
- 25. Cooper, Jeffery T, Stack, Gary M, and Cooper, Thomas P. "Intensive Medical Management of Ureteral Calculi." *Urology* 56, no. 4 (2000): 575-78
- 26. De Sio, Marco, Riccardo Autorino, Giuseppe Di Lorenzo, Rocco Damiano, Dario Giordano, Luca Cosentino, Umberto Pane, Ferdinando Di Giacomo, Salvatore Mordente, and Massimo D'Armiento. "Medical Expulsive Treatment of Distalureteral Stones Using Tamsulosin: A Single-center Experience." *Journal of Endourology* 20, no. 1 (2006): 12-6

- 28. Dellabella, Milanese, and Muzzonigro. "RANDOMIZED TRIAL OF THE EFFICACY OF TAMSULOSIN, NIFEDIPINE AND PHLOROGLUCINOL IN MEDICAL EXPULSIVE THERAPY FOR DISTAL URETERAL CALCULI." *The Journal of Urology* 174, no. 1 (2005): 167-72
- 29. El Said, Nouran O., Lamia El Wakeel, Khaled M. Kamal, and Abd El Reheem Morad.

  "Alfuzosin Treatment Improves The Rate and Time for Stone Expulsion in Patients with Distal Uretral Stones: A Prospective Randomized Controlled Study."

  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35, no. 5 (2015): 470-76
- 30. El-Gamal, El-Bendary, Ragab, and Rasheed. "Role of Combined Use of Potassium Citrate and Tamsulosin in the Management of Uric Acid Distal Ureteral Calculi."

  Urological Research 40, no. 3 (2012): 219-24
- 31. Erturhan, Erbagci, Yagci, Celik, Solakhan, and Sarica. "Comparative Evaluation of Efficacy of Use of Tamsulosin And/or Tolterodine for Medical Treatment of Distal Ureteral Stones." *Urology* 69, no. 4 (2007): 633-36
- 32. Ferre, Wasielewski, Strout, and Perron. "Tamsulosin for Ureteral Stones in the Emergency Department: A Randomized, Controlled Trial." *Annals of Emergency Medicine* 54, no. 3 (2009): 432-39.e2
- 33. Furyk, Chu, Banks, Greenslade, Keijzers, Thom, Torpie, Dux, and Narula. "Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial." *Annals of Emergency Medicine* 67, no. 1 (2016): 86-95.e2
- 34. Georgescu D I-RF, Multescu R, et al. The role of a1-blockers in the medical expulsive therapy for ureteral calculi-a prospective controlled randomized study comparing tamsulosin and silodosin. Farmacia, Vol 63, 2015;2(184-188)
- 35. M. Cenk Gurbuz, Haci Polat, Lutfi Canat, Mert Kilic, and Turhan Caskurlu. "Efficacy of Three Different Alpha 1-adrenergic Blockers and Hyoscine N-butylbromide for Distal Ureteral Stones." *International Brazilian Journal of Urology* 37, no. 2 (2011): 195-202

- 36. Han MC PY, Shim BS. Effect of Tamsulosin on the Expectant Treatment of Lower Ureteral Stones. Korean J Urol. 2006; 47(7):708-11
- 37. Hermanns, Sauermann, Rufibach, Frauenfelder, Sulser, and Strebel. "Is There a Role for Tamsulosin in the Treatment of Distal Ureteral Stones of 7 Mm or Less? Results of a Randomised, Double-Blind, Placebo-Controlled Trial." *European Urology* 56, no. 3 (2009): 407-12
- 38. Ibrahim, Ahmed K., Mahmood, Isam H., and Mahmood, Nada S. "Efficacy and Safety of Tamsulosin vs. Alfuzosin as Medical Expulsive Therapy for Ureteric Stones." *Arab Journal of Urology* 11, no. 2 (2013): 142-47
- 39. Itoh, Yasunori, Atsushi Okada, Takahiro Yasui, Ryousuke Ando, Keiichi Tozawa, Shoichi Sasaki, and Kenjiro Kohri. "Administration of the Selective Alpha 1A-adrenoceptor Antagonist Silodosin Facilitates Expulsion of Size 5-10 Mm Distal Ureteral Stones, as Compared to Control." *International Urology and Nephrology* 45, no. 3 (2013): 675-8
- 40. Itoh, Yasunori, Atsushi Okada, Takahiro Yasui, Shuzo Hamamoto, Masahito Hirose, Yoshiyuki Kojima, Keiichi Tozawa, Shoichi Sasaki, and Kenjiro Kohri. "Efficacy of Selective α1A Adrenoceptor Antagonist Silodosin in the Medical Expulsive Therapy for Ureteral Stones." *International Journal of Urology* 18, no. 9 (2011): 672-74
- 41. Kaneko, Tomoyuki, Hisashi Matsushima, Hirohiko Morimoto, Yasuo Tsuzaka, and Yukio Homma. "Efficacy of Low Dose Tamsulosin in Medical Expulsive Therapy for Ureteral Stones in Japanese Male Patients: A Randomized Controlled Study."

  International Journal of Urology 17, no. 5 (2010): 462-65
- 42. Kang, Dong II, Cho, Won Yeol, Kim, Tae Hyo, Chung, Jae Min, Park, Jisung, Yoon, Jang Ho, and Lee, Sang Don. "Effect of Tamsulosin 0.2 Mg on the Short-Term Treatment of Urinary Stones: Multicenter, Prospective, Randomized Study."

  Korean Journal of Urology 50, no. 6 (2009): 586-90
- 43. Keshvary M TR, Arab D. The effect of Tamsulosin and nifedipine in facilitating juxtavescial stones' passage. Medical journal of Mashhad university of Medical Sciences, 2006;48:425-30
- 44. Kim JW CD, Lee JG. Effect of tamsulosin on the expected treatment of upper and lower ureteral stones. *Korean Journal of Urology* 2007;48(7):724-30

- Enhance Lower Ureteral Stone Clearance with or without Shock Wave Lithotripsy?"

  Urology 64, no. 6 (2004): 1111-115
- 47. Lee, S. W., S. H. Woo, D.-S. Yoo, and J. Park. "Effect of Tamsulosin on Stone Expulsion in Proximal Ureteral Calculi: An Open-label Randomized Controlled Trial." *International Journal of Clinical Practice* 68, no. 2 (2014): 216-21
- 48. Liatsikos, Katsakiori, Assimakopoulos, Voudoukis, Kallidonis, Constantinides, Athanasopoulos, Stolzenburg, and Perimenis. "Doxazosin for the Management of Distal-ureteral Stones." *Journal of Endourology* 21, no. 5 (2007): 538-41
- 49. Lojanapiwat, B., W. Kochakarn, N. Suparatchatpan, and K. Lertwuttichaikul.

  "Effectiveness of Low-dose and Standard-dose Tamsulosin in the Treatment of
  Distal Ureteric Stones: A Randomized Controlled Study." *Journal of International Medical Research* 36, no. 3 (2008): 529-36
- 50. Lv, Jian, and Lin Tang. "Comparative Evaluation of Efficacy of Use of Naftopidil And/or Celecoxib for Medical Treatment of Distal Ureteral Stones." *Urolithiasis* 42, no. 6 (2014): 541-47
- 51. Mohseni MG, Hosseini SR, Alizadeh F. Efficacy of terazosin as a facilitator agent for expulsion of the lower ureteral stones. Saudi Medical Journal. 2006;27(6):838-40
- 52. Morúa, García, Montelongo, and Guerra. "Uso De Alfuzosina Para La Expulsión De Cálculos Del Tercio Distal Del Uréter." *Actas Urologicas Espanolas* 33, no. 9 (2009): 1005-010
- 53. Ochoa-Gómez, Raúl, Emilio Prieto-Díaz-Chávez, Benjamín Trujillo-Hernández, and Clemente Vásquez. "Tamsulosin Does Not Have Greater Efficacy than Conventional Treatment for Distal Ureteral Stone Expulsion in Mexican Patients." *Urological Research* 39, no. 6 (2011): 491-95
- 54. Pedro, Hinck, Hendlin, Feia, Canales, and Monga. "Alfuzosin Stone Expulsion Therapy for Distal Ureteral Calculi: A Double-Blind, Placebo Controlled Study." *The Journal of Urology* 179, no. 6 (2008): 2244-247

- 55. Pickard, Robert, Starr, Kathryn, Maclennan, Graeme, Lam, Thomas, Thomas, Ruth, Burr, Jennifer, Mcpherson, Gladys, Mcdonald, Alison, Anson, Kenneth, N&Amp; Apos, Dow, James, Burgess, Neil, Clark, Terry, Kilonzo, Mary, Gillies, Katie, Shearer, Kirsty, Boachie, Charles, Cameron, Sarah, Norrie, John, and Mcclinton, Samuel. "Medical Expulsive Therapy in Adults with Ureteric Colic: A Multicentre, Randomised, Placebo-controlled Trial." *The Lancet* 386, no. 9991 (2015): 341-49
  56. Porpiglia, Destefanis, Fiori, and Fontana. "Effectiveness of Nifedipine and
- 56. Porpiglia, Destefanis, Fiori, and Fontana. "Effectiveness of Nifedipine and Deflazacort in the Management of Distal Ureter Stones." *Urology* 56, no. 4 (2000): 579-82
- 57. Porpiglia, Francesco, Cristian Fiori, Gianpaolo Ghignone, Davide Vaccino, Michele Billia, Ivano Morra, Francesca Ragni, and Roberto M. Scarpa. "A Second Cycle of Tamsulosin in Patients with Distal Ureteric Stones: A Prospective Randomized Trial." *BJU International* 103, no. 12 (2009): 1700-703
- 58. Porpiglia, Ghignone, Fiori, Fontana, and Scarpa. "Nifedipine versus tamsulosin for the management of lower ureteral stones." *The Journal of Urology* 172, no. 2 (2004): 568-71
- 59. Porpiglia, Vaccino, Billia, Renard, Cracco, Ghignone, Scoffone, Terrone, and Scarpa. "Corticosteroids and Tamsulosin in the Medical Expulsive Therapy for Symptomatic Distal Ureter Stones: Single Drug or Association?" *European Urology* 50, no. 2 (2006): 339-44
- 60. Rahim J MA, Ashraf S, et al. Efficacy of Tamsulosin spontaneous expulsion in the treatment of distal ureteric stones. Pakistan Journal of Medical and Health Sciences. 2012;6(1):Jan-March 191-4.
- 61. Resim, Sefa, Hasan Ekerbicer, and Ahmet Ciftci. "Effect of Tamsulosin on the Number and Intensity of Ureteral Colic in Patients with Lower Ureteral Calculus."

  International Journal of Urology 12, no. 7 (2005): 615-20
- 62. Sameer, Lal, Shyam, Charak, K., Chakravarti, Sumit, Kohli, Supreeti, and Ahmad, Shamshad. "Efficacy of Nifedipine and Alfuzosin in the Management of Distal Ureteric Stones: A Randomized, Controlled Study." *Indian Journal of Urology* 30, no. 4 (2014): 387-391

- 63. Sayed, Mohamed Abdel-Basir, Ahmad Abolyosr, Medhat Ahmad Abdalla, and Ahmad Shehata El-Azab. "Efficacy of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Calculi." *Scandinavian Journal of Urology and Nephrology, 2008, Vol.42(1), P.59-62* 42, no. 1 (2008): 59-62
- 64. Sun, He, Ge, and Lv. "Efficacy of Selective α1D-Blocker Naftopidil as Medical Expulsive Therapy for Distal Ureteral Stones." *The Journal of Urology* 181, no. 4 (2009): 1716-720
- 65. Sur, Shore, L'esperance, Knudsen, Gupta, Olsen, and Shah. "Silodosin to Facilitate Passage of Ureteral Stones: A Multi-institutional, Randomized, Double-blinded, Placebo-controlled Trial." *European Urology* 67, no. 5 (2015): 959-64
- 66. Vincendeau, S., Bellissant, Houlgatte, Doré, Bruyère, Renault, Mouchel, Bensalah, and Guillé. "Tamsulosin Hydrochloride vs Placebo for Management of Distal Ureteral Stones: A Multicentric, Randomized, Double-blind Trial." Archives of Internal Medicine 170, no. 22 (2010): 2021-027
- 67. Wang, Chung-Jing, Shi-Wei Huang, and Chien-Hsing Chang. "Efficacy of an Alpha1 Blocker in Expulsive Therapy of Lower Ureteral Stones." *Journal of Endourology* 22, no. 1 (2008): 41-6
- 68. Wang, Chung Jing, Po Chao Tsai, and Chien Hsing Chang. "Efficacy of Silodosin in Expulsive Therapy for Distal Ureteral Stones: A Randomized Double-blinded Controlled Trial." *Urology Journal* 13, no. 3 (2016): 2666-71
- 69. Yencilek, Faruk, Sakıp Erturhan, Onder Canguven, Hakan Koyuncu, Bulent Erol, and Kemal Sarica. "Does Tamsulosin Change the Management of Proximally Located Ureteral Stones?" *Urological Research* 38, no. 3 (2010): 195-99
- 70. Yilmaz, Erdal, Batislam, Ertan, Basar, Mehmed Murad, Tuglu, Devrim, Ferhat, Mehmet, and Basar, Halil. "The comparison and efficacy of 3 different α1-adrenergic blockers for distal ureteral stones." *The Journal of Urology* 173, no. 6 (2005): 2010-012
- 71. Zehri, Ather, Abbas, and Biyabani. "Preliminary Study of Efficacy of Doxazosin as a Medical Expulsive Therapy of Distal Ureteric Stones in a Randomized Clinical Trial." *Urology* 75, no. 6 (2010): 1285-288

- 72. Zhou, Shui, Gen Lu, and Jian Hui. "Comparing Efficacy of  $\alpha$  1 D-receptor Antagonist Naftopidil and  $\alpha$ 1A/D-receptor Antagonist Tamsulosin in Management of Distal Ureteral Stones." *World Journal of Urology* 29, no. 6 (2011): 767-71
- 73. Autorino, Sio, Damiano, Lorenzo, Perdonà, Russo, Quarto, Cosentino, and D'Armiento. "The Use of Tamsulosin in the Medical Treatment of Ureteral Calculi: Where Do We Stand?" *Urological Research* 33, no. 6 (2005): 460-64
- 74. Yuksel, Mustafa, Serdar Yilmaz, Husnu Tokgoz, Soner Yalcinkaya, Serkan Baş,
  Tümay Ipekci, Ali Yildiz, Nihat Ates, and Murat Savas. "Efficacy of Silodosin in the
  Treatment of Distal Ureteral Stones 4 to 10 Mm in Diameter." *International Journal*of Clinical and Experimental Medicine 8, no. 10 (2015): 19086-92
- 75. Coll, Deirdre M, Michael J Varanelli, and Robert C Smith. "Relationship of Spontaneous Passage of Ureteral Calculi to Stone Size and Location as Revealed by Unenhanced Helical CT." *AJR. American Journal of Roentgenology* 178, no. 1 (2002): 101-3
- 76. Hubner WA, Irby P, Stoller ML. Natural history and current concepts for the treatment of small ureteral calculi. European Urology. 1993; 24(2):172-6
- 77. Morse RM, Resnick MI. Ureteral calculi: natural history and treatment in an era of advanced technology. he Journal of Urology, 1991;145(2):263-5
- 78. Sfoungaristos, Stavros, Adamantios Kavouras, and Petros Perimenis. "Predictors for Spontaneous Stone Passage in Patients with Renal Colic Secondary to Ureteral Calculi." *International Urology and Nephrology* 44, no. 1 (2012): 71-79
- 79. Tchey, Dong-Un, Ha, Yun Sok, Kim, Won Tae, Yun, Seok Joong, Lee, Sang Cheol, and Kim, Wun Jae. "Expectant Management of Ureter Stones: Outcome and Clinical Factors of Spontaneous Passage in a Single Institution's Experience." *Korean Journal of Urology* 52, no. 12 (2011): 847-51
- 80. Ueno, Kawamura, Ogawa, and Takayasu. "Relation of Spontaneous Passage of Ureteral Calculi to Size." *Urology* 10, no. 6 (1977): 544-46
- 81. Ye, Zhangqun, Zeng, Guohua, Yang, Huan, Tang, Kun, Zhang, Xiaochun, Li, Hong, Li, Weibing, Wu, Zhong, Chen, Lingwu, Chen, Xingfa, Liu, Xiankui, Deng, Yaoliang, Pan, Tiejun, Xing, Jinchun, Wang, Shusheng, Cheng, Yue, Gu, Xiaojian, Gao, Wenxi, Yang, Jianggen, Zhang, Yonghai, Mi, Qiwu, Qi, Lin, Li, Jiongming, Hu, Weilie, Liang, Peiyu,

Sun, Zhaolin, Xu, Changbao, Long, Yongfu, Liao, Yongbin, Liu, Siping, Liu, Guoqing, Xu, Xun, He, Wei, Chen, Zhiqiang, and Xu, Hua. "Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial." *European Urology*, 2017, European Urology

- 82. Skolarikos, A., Laguna, M.P., Alivizatos, G., Kural, A.R., and De La Rosette, J.J.M.C.H."The Role for Active Monitoring in Urinary Stones: A Systematic Review.(Clinical Report)." *Journal of Endourology* 24, no. 6 (2010): 923-30
- 83. Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MTWT. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD008509. DOI: 10.1002/14651858.CD008509.pub2
- 84. Seitz, Liatsikos, Porpiglia, Tiselius, and Zwergel. "Medical Therapy to Facilitate the Passage of Stones: What Is the Evidence?" *European Urology* 56, no. 3 (2009): 455-71
- 85. Singh, Alter, and Littlepage. "A Systematic Review of Medical Therapy to Facilitate Passage of Ureteral Calculi." *Annals of Emergency Medicine* 50, no. 5 (2007): 552-63
- 86. Lotan, Gettman, Roehrborn, Cadeddu, and Pearle. "Management Of Ureteral Calculi: A Cost Comparison And Decision Making Analysis." *The Journal of Urology* 167, no. 4 (2002): 1621-629

AUA- American Urological Association

ESWL- Extra Corporal Shock Wave Lithotripsy

**URs- Ureteroscopy** 

**PCNL- Percutaneous Nephrolithotomy** 

**RCT- Randomized Control Trial** 

Table 1: Demographics of Included studies

Author, yr.	Age (mean+-SD unless	Gender (M:F)	Stone size (mean+-SD unless	Expulsion rate	Expulsion time, d
	specified)		specified)		
Abdel-Meguid	Med 36 (19-72)	53:22	Median 6 (4-10)	42/75	<6m 17; 7-10m 20
2010					
Agrawal 2009	35.3 (22-58)	24:10	6.35 (4-8)	12/34	24.5
Ahmad 2015		48	5.78 (4–8)	26/48	
Ahmed 2010	38.9±13.3	19:9	5.39±1.81	14/28	13.9±6.99
Aldemir 2011	43.5 ± 16.6 (18–71)	19:10	6.6 ± 1.7 (4–10)	11/29	7
Autorino, 2005	43	21:11	5.7 (3–10)	19/32	7.4±2.2
Alizadeh 2014	19-54	32:14	0.83±4 .81	30/46	4.7±8.03
Al-Ansari 2010	36.13 ± 9.32		6.04+-2.5	28/46	9.87+-5.4
Bajwa 2013	33.87+-9.61	19:11	6.63+-1.45	11/30	20.93+-4.43
Balci 2014	34.5±10.2	18:7	6.3 ± 1.5	9/25	10.3
Borghi, 1994	43 ± 14	25:18	6.8 ± 2.9	24/43	16.4
Cervenakov, 2002	17–74	33:18		32/51	3.4
Chau 2011	48.6 ± 11.8		6.9 ± 1.5	17/34	-
Coll 2002				115/172	

Cooper, 2000		35	3.86	19/35	11.2
Dellabella, 2003	38.1 ± 10.6 (18-58)	18:12	5.8 ±1.3 (4-11)	21/30	4.6
Dellabella, 2005	39.8 ± 12.7	50:20	6.2 ± 1.7 (4-11.8)	45/70	5
De Sio 2006	44.5 ± 11.3	26:20	6.4 ± 1.3	27/46	7.5±1.8
El-Gamal 2012	36.2 ± 6	34:12	7.7 ± 1.63	12/46	
ElSaid 2015	32.1+-9.2	16:10	5.9+-1.9	7/26	Median 19 (8-25)
Erturhan, 2007				26/60	
Ferre 2009	45 ± 12		3.8 ± 1	24/37	Median 3
Furyk 2015	46 (37–55)			127/155	Median 11
Georgescu 2015	45.14+-11.58	26:24	5.1+-2.02	26/50	12.03+-6.22
Gurbuz 2011	40.3 ± 15.9	22:11	7.13 ± 1.11	3/33	10.55+-6.21
Han, 2006	42.7	22:10	4.3+-0.61	17/32	8.3+-3.8
Hermanns 2009	41 (33–54)	36:9	3.8 (3.4-4.3)	40/45	Median 10
Hubner 1993	47 (10-74)	64:36		30/100	
Ibrahim 2013	36.71 ± 11.64	25:7	5.65+-1.25	14/32	
Itoh 2011	56.5 ± 10.1	92	5.67+-2.1	46/92	15.19+-7.14
Itoh 2013	55.8 ± 10.4	56	4.87+-1.98	31/56	13.4+-5.9
Kaneko 2010	45 ± 8.7 (28–61)	34	4.8±2.1	17/34	17±11

	nagedocureterdectorde. ASGCAYCUMUNERS BITMY3BBAR600 patre/A81(DORSCOOPERDIEDGINOBA) nat 03/02/18. For personal use only.	ation but has vet to undergo convediting and proof correction. The final published version may differ from this proof
DOULIA	<b>Unattendedston</b>	wed and accepted for publication, but has yet to und

Kang 2009	45.19+-12.27	12:9	0.47+-0.08	8/21	
Keshvary, 2006	n/a	24	6.8	11/24	14.2
Kim 2007	45.7+-13.8	24:18	5.2+-2.6	18/42	18.5+-6.9
Kirac 2013	29.3 ± 7.1	23:16	6.98 ± 2.1	19/39	15.3 ± 5.3
Küpeli, 2004	43.74 (21–65)	15	4.9 (3–5)	3/15	
Lee 2014	47.9 ± 11.4	33:21	3.65±1.15	25/54	19.6±8.5
Liatsikos, 2007	46.33 ± 10.74	6:9	3.00 ± 1.46	9/15	8.8±1.09
	43.75 ± 11.16	7:9	7.69 ± 1.35	7/16	12.1±1.35
Lojanapiwat, 2008	46.52 ± 13.63	20:5	6.70 ± 1.66	1/25	23±0
Lv 2014	33.75+-5.24	18:15	7.3+-1.2	20/33	10.65+-2.92
Miller 1999	36.5			62/75	
Mohseni, 2006	39.3 ± 14.2 (18-61)	24:8	6.6± 3.1 (3.5-10)	20/32	5.9±2.7
Morua 2009	36.2 ± 12.2		6.4+-1.8	6/15	13.16+-11.5
Morse 1991	11-88	242:136		228/378	
Ochoa-Gomez	38.2 ± 12.4	21:12	5.2 ± 0.39	23/33	23 ± 6.36
2011					
Pedro, 2008	42.03 ± 12.85	27 : 8	4.07 ± 1.13	27/35	8.5±6.99
Pickard 2015	42.8 ± 12.3	294:85	4.5+-1.7	303/379	15.9+-11.3(84)

only.

Journal of Endourology vy of Conservatively Managddc <b>uratra</b> dc <b>.borde.A8</b> 67.046.U.MURB.986.B1161431818A86006 pratsérR81(D70818)1	ewed and accepted for publication. but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
History of	ewed a

					2
Porpiglia, 2000	49 (18-70)	24:24	5.5 ± 1.4	17/48	20
Porpiglia, 2004	42.7 ± 16	16:12	5.4 ± 1.49	12/28	12
Porpiglia, 2006	45.2 ± 0.88 (33–50)	12:12	5.5+-0.13	8/24	
Porpiglia, 2009	46 ± 14.6	23:22	6.03+-0.81	22/45	5
Rahim 2012	33.84+-12.13	31:14	6+-0.53	22/45	19.18+-4.66
Resim, 2005	33.50 ± 9.7	23:7	7.80 ± 2.2	22/30	
Sameer 2014	33.06 ± 8.76	23:12	6.37 ± 1.85	7/35	12.29+-9.46
Sayed, 2008	37.1 ± 9.8 (18-58)	35:10	6.4±1.3 (5-10)	23/45	12.5±2.12
Sfoungaristos	42.40 ± 13.75		7.12±3.57	36/68	
Sur 2015	47 ± 15		5.5±1.6	52/117	-
Sun 2009	37.8+-10.2	24/6	5.7+-1.2	8/30	Median (6 (IQR: 5-
					7))
Tchey 2011	42.6		3.9±1.8	566/656	
Ueno 1977			4.0 ± 1.5	286/520	
Vincendeau 2010	39.0 ± 11.4	52:9	3.2±1.2	43/61	9.6+-9.8
Wang, 2008	50.9 ± 9.6	23:8	6.5 ± 1.4	17/31	10.1±3
Wang 2016	51.51 ± 10.03		6.46±1.31	48/62	6.31+-2.13
Yencilek 2010	33.5 ± 10.1 (22–51)	30:20	6.6±2.7	15/50	11.6+-4.1

					2
Ye 2017	40 ± 12.3	605:1049	5.7 ± 1.8	1300/1654	10.3
Yilmaz, 2005	41.60 ± 12.01	19:9	6.07 ± 1.41	15/28	10.5±2.12
Yuksel 2015	35.23+-11.2	20:15	6.35+-1.57	25/35	12.91+-6.14
Zehri 2010	33.62	25:7	5.49	12/32	12.5+-1.17
Zhou 2011	34.79 ± 9.63	27:16	6.61 ± 0.74	13/43	9.4 ± 2.48

Table 2: Cumulative analysis of results for the included studies

Parameter	Spontaneous Stone Passage Rate/Total patients (%)		
Overall	4277/6642 (64.4%)		
Location			
- Upper Ureter	348/709 (49.1%)		
- Mid Ureter	111/191 (58.1%)		
- Lower Ureter	3442/5056 (68.1%)		
Size			
- <5mm	1353/1797 (75.3%)		
- >5mm	1109/1800 (61.6%)		




Figure 1: Flowchart for article selection process of the review



Figure 2: Risk of bias graph: review authors' judgements about each risk of

bias item presented as percentages across all included studies.